completely agree with lynchfan.the pie is big enough for many players to operate.byke usp is its 220 plus agents.there is big number of people in small town india who will require a physical face for their booking and travel.byke uses the results of chartering buisness to open leased hotels.they have multiple streams of revenue.recent research house reports puts their fy 18 pat at 43 cr.at 30 p/e we looking at 1300 cr mcap,more than double from current mcap.i think its a safe stock to be in.
Posts tagged Value Pickr
Cupid Ltd – Helping the world play safe! (12-09-2015)
Female Condoms are being promoted extensively in the US. The product as well as the market itself, is relatively at a nascent stage. It's difficult to predict the market size say 10 years from now, but it does have the potential to surprise all of us on the upside.
Attaching an e-newsletter recd. from National Female Condom Coalition which will shed some light on the efforts being made to promote female condoms. http://www.nationalfccoalition.org
National Female Condom Coalition
Sept. 8, 2015
Female condom action at the US Conference on AIDS
Are you going to the 19th annual U.S. Conference on AIDS (USCA) in Washington, D.C. Sept. 10 – 13 and want to know where the female condom (FC) action will be? Below is a list of the FC activities going on at USCA. We hope you will join us for any or all of these festivities. If you know of other FC activities happening at the conference, please email us details!
Can't make it to USCA? Follow the national conversation with #2015USCA. Also, learn what is going on in the world of FCs as we live tweet throughout the conference from @NatlFCCoalition.
Speak up at our female condom action center
We’re bringing our Imagine the Future of Female Condoms campaign to the capital with our action center. Stop by our booth in the conference exhibit hall to send your personal message urging the U.S. FDA to pave the way for more female condom options. Have your picture taken for our photo petition; sign our petition to the FDA; connect with female condom advocates from across the U.S.; and learn about other female condom options available around the world.
Can't make it to USCA? You can take action online by checking out our campaign page and signing our online petition!
What: National Female Condom Coalition booth and action center
When: Thursday, Sept. 10 - Saturday, Sept. 12, 10 a.m. - 5 pm.
Where: Conference exhibit hall, booth #702
Small bites and big ideas – join us for an evening female condom reception
CHANGE, 30 for 30 Campaign, NFCC, and the Female Health Company invite you to a special reception commemorating the fourth annual Global Female Condom Day. Join us for an evening of conversation about the future of female condom advocacy with leading U.S. FC advocates, a photo gallery of FC users from around the globe and a special showing of the “Female Condoms Are _____” film contest winner, “My power, my pleasure, my protection.” An RSVP is required, so please contact Devan Shea to reserve your spot!
What: Female condom reception
When: Thursday, Sept. 10, 6 - 8 p.m.
Where: Provision No. 14, 2100 14th St NW
RSVP to Devan Shea at dshea@genderhealth.org
Organizing session: Improving health departments’ female condom communications
Do you work at or with a city, country or state health department? Be sure to join us for "Messaging Matters: Improving Health Departments’ Female Condom Communications." This interactive session will include discussion of assessment outcomes of U.S. health departments’ online female condom communications; recommendations for effective female condom education and promotion; strategies for discussing anal use of female condoms in the absence of safety and efficacy data; and advocacy strategies for stronger female condom promotion.
Come to this organizing session and share your local experiences regarding health departments’ involvement in female condom education and programming. Together we will develop concrete action steps to improve female condom efforts with/at your local health departments.
Presenters will include Natalie Cramer, NASTAD; Elizabeth Kelvin, City University of New York (CUNY) School of Public Health; and Jessica Terlikowski, AIDS Foundation of Chicago. Let us know if we can count on seeing you there!
What: Female condom organizing session
When: Friday, Sept. 11, 4:30 – 6 p.m.
Where: Farragut North, Meeting Level 3
Click here to RSVP!
ABOUT US
The National Female Condom Coalition (NFCC) is a partnership of U.S. and U.S.-based advocates, researchers, health departments, community-based and national organizations that advances a mission to increase awareness, acceptance, access, and use of female condoms.
National Female Condom Coalition
200 West Jackson Blvd., Suite 2100
Chicago IL 60606
Shaily Engineering Plastic (12-09-2015)
"It also plans to double sourcing and suppliers from India by 2020."
Ikea plans to double the suppliers as well...which means shaily may have competition from other players . Though I don't expect its current orders from ikea to reduce due to other vendors but the future growth pie might have to be shared with other vendors. Nevertheless shaily should get decent growth in orders from ikea with its establishment in india.
Mutual fund investment first time (12-09-2015)
With due respect to the comments, i dont want to hold funds in which fund manager has changed, thats too much risk. is there another fund with a good fund manager as a replacement. I am not in a hurry but i want to be out sooner then later
Vivek Gautam Portfolio (12-09-2015)
Santosh How do u calculate YTD returns? I havent gone into much details for it but after your prodding I checked on Moneycontrol which is giving a yearly return of 44%.But several of buys have been recent less then a year.
Yes after PF appreciation preservation of PF gains is also important so diversification becomes necessary imho.
TCS is the only largecap anchor stock in my PF but I hv been holding it since IPO @ 212 in 2004.If we take international context the opp size remains big.Reasons for investing in TCS i have explained earlier in the thread.
Mayur story remains intact due to increasing high margin exports both OEM and in general from low margin footwear,foray into lucrative B2C, high ROCE business under ethical promoter with execution .
Marksans is play on a promoter in right age (in 40s) out to prove himself with growth mindset,operating in lucrative niche segment with less FDA issues,timely acquisitions,amongst the few players n softgel segment,attractive mktcap vs opp size,exceptionally high return ratios.
Santosh why are you not so positive on kaveri?Shudnt we focus on next 1-2 years growth prospects n not be dismayed by a bad qtr which is infact 80% of full year for kaveri?
Srikanth VRL promoter is real smart.he sold of kannada paper to TOI at a high margin,Started another Kannada paper and brought back most of the staff from TOI. Giving a kick to a giant like TOI shows guts.yes he is 4 times ex BJP MP but I take it as a positive with central govt of BJP.
Byke hospitality – Truly asset light? (12-09-2015)
Byke , Oyo are significantly small in size compared to the huge but fragmented market size. Several years of growth opportunities are available. There is enough room for lots of players .
Bykes management in a analyst meet said they are confident of fending of competition from online players because of the high manual intervention still necessary in the room aggregation business.
Oyo's start up story is really inspiring. Its simplistic standardization is refreshing. But going through the reviews you would find what byke means by requirement for 'manual intervention'.
Byke hospitality – Truly asset light? (12-09-2015)
Byke , Oyo are significantly small in size compared to the huge but fragmented market size. Several years of growth opportunities are available. There is enough room for lots of players .
Bykes management in a analyst meet said they are confident of fending of competition from online players because of the high manual intervention still necessary in the room aggregation business.
Oyo's start up story is really inspiring. Its simplistic standardization is refreshing. But going through the reviews you would find what byke means by requirement for 'manual intervention'.
NGL Fine Chem-Re Rating Possible? (12-09-2015)
Hello All,
I attended the AGM of NGL Fine y'day and here are my key takeaways,
- The co. is not looking to add products aggressively,will commercialise two products its been working on for almost a year,one each in Human API and Vet API.
- End-use of Vet APIs is targeted towards Cattle.
- The co. is focused on products that've a small market size,it doesn't want to focus on areas where biggies would enter. It's happy to have 15-20-25% type market share in products with market size of 15-20-25 or roughly 50 crs. One of its products contributed 20-22.5 cr sales out of total sales in fy15 and the rest was from other 10-12 products. It has maximum 6-7 competitors in each product category and the market size along with competitive structure has remained static.
- New products are also selected on the basis of small size that would discourage biggies to enter and that belong to chemical family of existing products,not on the basis of opportunity size or scope for higher margins.
- The co. faces competition from China in Animal API space apart from Sequent (Alivira) and Omkar (Lasa) in India and a couple of other small players. The co. is unfazed about yuan devaluation.
- Pricing for some products is done on contractual basis and some products are priced as per prevailing prices in the market. Margins would be in the range of 13%-18%,the range indicating worst and best times.
- Top 10 customers contribute around 40% of the revenues,Top 5 contribute around 25%. All sales of co.'s products are to non-regulated markets directly or may be routed through a distributor based in another country. LatAm,Africa,SEA and neighbouring Indian countries are main end-user markets,the co. exports to 35 odd countries in total. Co. sells to 4/10 top Animal Health formulations cos. Majority of sales done in India are for Human APIs.
- The co. plans to do a CAPEX of 20 crs. in 1-2 years to install an R&D facility and expand capacity by 40%. Current R&D facility has 10 employees,2 PhDs,needs new facility to do more work.
- Management doesn't like to think in terms of long-term vision or goals,thinks in terms of 1-2-3 year time-frame. It expects to grow at around 15-18% types rate at best. The co. became big in last 10 years due to expansion in market size of its products which were very tiny at that point in time. Further,growth will not come from expansion in market size of existing products significantly but by addition of new products,which the co. plans to do slow and steady.
Overall,I found the Management quite conservative,looking to maintain existing position more than growing.
P.S. - The management also intends to develop a new product for paints industry,its entered into a tripartite agreement with two British cos,the product is just a gamble on some regulatory change envisaged in near future,will be a new line of business if things work and will put up separate capacity for the same but at the moment its just a wild bet. Missed knowing if the product is being developed for international or local market.
Disc. - No investments in the co.
Prof. Sanjay Bakshi’s Lecture link (12-09-2015)
I have learnt a helluva lot from Prof Bakshi, and for free
I viewed through this talk and there is something striking about this, not only from an investment learning perspective but also on how various propositions are made. It often occurs to me that there are many ways one gets convinced about various propositions or arguments.
There are of course deductive arguments which if sound and valid are true beyond doubt. The field of mathematics works only on deductive arguments with some starting axioms.
Then there are inductive arguments where the conclusion does not always follow from the premises but is by and large true. Inductive arguments are risky because while they do a job of making a lot of sense, acting on inductive validated arguments can fail at times, under certain circumstances and in fact fail even randomly. For instance when a grocer runs a firesale of yesterday's oranges, you pick an orange or two from the heap and then decide whether it is worth buying at the price or not. If you decide either to buy or to discard the heap your conclusion may or may not be true. And you know that.
Most of life including investing (even including physical sciences) is driven by inductive based judgements, if you will. The art therefore is to know which to believe and which to discard. For instance if I always get-up before sun rise I can claim the sun rises only because I get up. You know it is absurd but then unless you can set-up an experiment to falsify it you will have to accept what I say because you cannot disprove it. (BTW charlatans work that way)
So can we learn the art, so we may know what to believe and what not to? The answer is an 'inductive' yes Broadly the inductive arguments can be strong or weak; based on valid evidence, generalization, application, from analogy, an inference to the best explanation and so forth. There are also fallacies or common flaws that weaken an inductive argument. Some of them include what are called ad-hominem arguments - attack the person instead of the argument, and what is relevant here - which is "appeals to authority" . An 'appeals to authority' argument makes the case that a so-and-so has said it, so the argument must be valid.
Now, coming to the point, what I found striking about the talk was that nearly all the propositions were based on 'appeals to authority'. Either Charlie or Buffett or an author or Ben G etc have said it so it must be valid.
Warm regards,
Sources on arguments:
- Coursera.org course on: Think again: How to reason and argue.
- Probability and inductive logic by Ian Hacking
Vivek Gautam Portfolio (12-09-2015)
Great going @Vivek_6954.
Thanks for sharing your PF details.
Your PF has large number of stocks and is well diversified. Core stocks seems like good long term compounders. I think last few yrs has been really good for your PF. Its a good strategy to diversify for wealth preservation and grow steadily with limited down side as PF size grows.
I have a very concentrated PF. I am very much interested in your PF returns, YTD, Jan to Sept, this is just for academic purpose, if you can share , also 1 yr return, as I wish to evaluate conc vs diversified PF strategy both in good and bad times of market.
I think you can reduce no of stocks going forward, Gareware seems to be a great pick, but you can reduce TCS and Mayur, kaveri.